Display options
Cite
Tan P, Wei A, Mithraprabhu S, et al. Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood Cancer J. 2014;4:e170doi: 10.1038/bcj.2013.68.
Tan, P., Wei, A., Mithraprabhu, S., Cummings, N., Liu, H. B., Perugini, M., Reed, K., Avery, S., Patil, S., Walker, P., Mollee, P., Grigg, A., D'Andrea, R., Dear, A., & Spencer, A. (2014). Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood cancer journal, 4e170. https://doi.org/10.1038/bcj.2013.68
Tan, P, et al. "Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome." Blood cancer journal vol. 4 (2014): e170. doi: https://doi.org/10.1038/bcj.2013.68
Tan P, Wei A, Mithraprabhu S, Cummings N, Liu HB, Perugini M, Reed K, Avery S, Patil S, Walker P, Mollee P, Grigg A, D'Andrea R, Dear A, Spencer A. Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood Cancer J. 2014 Jan 10;4:e170. doi: 10.1038/bcj.2013.68. PMID: 24413064; PMCID: PMC3913937.
Copy Download .nbib Format: NLM
Share it on

Blood Cancer J. 2014 Jan 10;4:e170. doi: 10.1038/bcj.2013.68.

Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome.

Blood cancer journal

P Tan, A Wei, S Mithraprabhu, N Cummings, H B Liu, M Perugini, K Reed, S Avery, S Patil, P Walker, P Mollee, A Grigg, R D'Andrea, A Dear, A Spencer

Affiliations

  1. Department of Clinical Haematology, Alfred Hospital, Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia.
  2. Australian Centre for Blood Diseases, Biotechnology Division, Eastern Clinical Research Unit, Monash University, Melbourne, Victoria, Australia.
  3. Institute of Medical and Veterinary Science, Department of Haematology and Centre for Cancer Biology, Adelaide, South Australia, Australia.
  4. Division of Cancer Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
  5. Department of Haematology, Austin Hospital, Melbourne, Victoria, Australia.

PMID: 24413064 PMCID: PMC3913937 DOI: 10.1038/bcj.2013.68

Abstract

Therapeutic options are limited for elderly patients with acute myeloid leukemia (AML). A phase Ib/II study was undertaken to evaluate the maximum-tolerated dose (MTD) and preliminary efficacy of the pan-histone deacetylase inhibitor panobinostat (LBH589) in combination with azacitidine in patients with AML or high-risk myelodysplastic syndrome (MDS) naïve to intensive chemotherapy. Thirty-nine patients (AML=29, MDS=10) received azacitidine 75 mg/m(2) subcutaneously (days 1-5) and oral panobinostat (starting on day 5, thrice weekly for seven doses) in 28-day cycles until toxicity or disease progression. Dose-limiting toxicities during the phase Ib stage were observed in 0/4 patients receiving 10 mg panobinostat, in 1/7 patients (fatigue) receiving 20 mg, in 1/6 patients (fatigue) receiving 30 mg and in 4/5 patients (fatigue, syncope, hyponatremia and somnolence) receiving 40 mg. In phase II, an additional 17 patients received panobinostat at a MTD of 30 mg. The overall response rate (ORR=CR+CRi+PR) in patients with AML was 31% (9/29) and that in patients with MDS was 50% (5/10). After a median follow-up of 13 months, the median overall survival was 8 and 16 months in patients with AML and MDS, respectively. Increased histone H3 and H4 acetylation was a useful early biomarker of clinical response. Combining panobinostat with azacitidine was tolerable and clinically active in high-risk MDS/AML patients, warranting further exploration.

References

  1. Lancet Oncol. 2009 Mar;10(3):223-32 - PubMed
  2. J Clin Oncol. 2002 May 15;20(10):2429-40 - PubMed
  3. Blood. 2012 Mar 8;119(10):2346-57 - PubMed
  4. Am J Hematol. 2009 Sep;84(9):560-4 - PubMed
  5. Leukemia. 2006 Feb;20(2):212-7 - PubMed
  6. Nat Genet. 1999 Jan;21(1):103-7 - PubMed
  7. Blood. 2009 Sep 24;114(13):2764-73 - PubMed
  8. Blood. 2007 Oct 1;110(7):2302-8 - PubMed
  9. Blood. 2010 Jul 22;116(3):354-65 - PubMed
  10. Blood. 2006 Jul 15;108(2):419-25 - PubMed
  11. Blood. 2009 Jul 30;114(5):937-51 - PubMed
  12. J Clin Invest. 1985 Feb;75(2):547-57 - PubMed
  13. Blood. 1997 Mar 15;89(6):2079-88 - PubMed
  14. Leukemia. 2013 Aug;27(8):1628-36 - PubMed
  15. Blood. 2008 Feb 1;111(3):1060-6 - PubMed
  16. Oncotarget. 2010 May;1(1):34-42 - PubMed
  17. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 - PubMed
  18. Haematologica. 2013 Feb;98(2):208-16 - PubMed
  19. Nat Med. 2007 Jun;13(6):730-5 - PubMed
  20. Br J Haematol. 2013 Aug;162(4):559-62 - PubMed
  21. Epigenetics. 2012 Aug;7(8):875-82 - PubMed
  22. Cancer Res. 2006 Jun 15;66(12):6361-9 - PubMed
  23. J Clin Oncol. 2003 Dec 15;21(24):4642-9 - PubMed
  24. Eur J Haematol. 2013 Apr;90(4):345-8 - PubMed
  25. Leukemia. 2013 Jun;27(6):1358-68 - PubMed
  26. Cancer. 2012 Feb 15;118(4):1014-22 - PubMed
  27. J Clin Oncol. 2012 Jul 20;30(21):2670-7 - PubMed
  28. Leukemia. 2013 Jul;27(7):1588-92 - PubMed
  29. J Clin Oncol. 2009 Apr 10;27(11):1850-6 - PubMed
  30. Cancer. 2007 Mar 15;109(6):1114-24 - PubMed

Publication Types